transcription factor targeted compound library

Well-chosen 695 compounds with unique structures targeting transcription factor;

A unique collection of 3404 compounds in clinical trial phases for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 910 DNA Damage & Repair related compounds for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 1544 metabolism diseases related compounds for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 4630 approved and clinical drugs for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 2427 of orally active compounds for high-throughput screening and high-content screening.

A unique collection of 1268 cancer cellular metabolism related compounds for cancer research and high throughput screening (HTS) and high content screening (HCS);

Well-chosen 953 compounds related to epigenetic regulation for research in epigenetics, high throughput screening (HTS) and high content screening (HCS) for new drugs;

A unique collection of 3188 compounds with known anti-cancer activity for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 449 compounds acting on immune-oncology therapeutic targets can be used for high throughput and high content screening；

A unique collection of 1702 compounds with anti-lung cancer therapeutic activity or targeting lung cancer’s major signaling pathways, can be used for anti-lung cancer drug discovery and mechanism study；

A unique collection of 334 nucleoside and nucleotide analogues, can be used for research and development of anti-viral, anti-tumor, anti-fungal, and anti-depressive drugs;

1066 types of active small molecules associated with pyroptosis for high-throughput and high-content screening.

791 peptides can be used in peptide drug development and signaling transduction and mechanism study;

A collection of 950 natural product molecules originated from Mongolian medicine, which can be used for high-throughput and high-content screening.

A unique collection of 1147 monomers from 60 TCM plants, a powerful tool for anti-COVID-19 drug discovery, can be used for HTS and HCS screening；

A unique collection of 1040 anti-virus compounds effective for new anti-virus drugs high throughput screening and high content screening;

A unique collection of 2540 compounds targeting CNS signaling for high throughput screening (HTS) and high content screening (HCS) for new drugs;

A unique collection of 7234 compounds with anti-cancer activity for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 904 antibacterial bioactive compounds, a powerful tool for antibacterial drug development;

A unique collection of 812 promising or approved mitochondria-targeted compounds including Idebenone, the only approved drug targeting mitochondria, for research in mitochondrial medicine;

A unique collection of 1197 stem cell differentiation signaling targeted compounds for high throughput and high content screening;

A unique collection of 2247 anti-obesity compounds for high throughput and high content screening;

A collection of 17100 small molecule compounds with validated activity for high throughput screening (HTS), high content screening (HCS), cell induction, and target identification;

It is well-selected from Bioactive compound library Plus (D7800), from which 1-15 compounds with the highest scores (activity value, pharmacological properties, structure-diversity, etc.) were chosen. This library consists of 989 compounds without compro

A unique collection of 492 compounds targeting lipid metabolism, can be used for high-throughput screening (HTS) and high-content screening (HCS).

A unique collection of 677 cell cycle related compounds for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 1283 endogenous metabolism-related compounds for research in endogenous metabolism-related diseases and drug screening.

A unique collection of 1940 GPCR-active agents for high throughput screening and high content screening for GPCR drug discovery, and new GPCR target identification and research;

A unique collection of 683 diabetes related compounds;

A unique collection of 1513 neurotransmitter receptor compounds, can be used for HTS and HCS screening；

A unique collection of 1408 cardiovascular diseases related compounds for high throughput screening (HTS) and high content screening (HCS);

A collection of 747 natural product molecules originated from Tibetan medicine, which can be used for high-throughput and high-content screening.

A unique collection of 531 nuclear receptor signaling targeted compounds for high throughput and high content screening;

A unique collection of 565 glutamine metabolism related compounds can be used for high throughput screening (HTS) and high content screening (HCS), and also is an effective tool for research in glutamine metabolism and cancer;

1545 compounds associated with colorectal cancer that can be used for high-throughput and high-content screening.

A unique collection of 1939 compounds with anti-breast cancer therapeutic activity or targeting breast cancer’s major signaling pathways, can be used for anti-breast cancer drug discovery and mechanism study；

1787 species of compounds related to liver cancer that can be used in anti-liver cancer drug development and pharmacological studies.

A unique collection of 1867 compounds with anti-ovarian cancer therapeutic activity, can be used for anti-ovarian cancer drug discovery and pharmacological study;

A unique collection of 101 compounds with defined hematopoietic toxicity for high throughput and high content drug screening;

A unique collection of 469 histone modification related compounds for high throughput screening (HTS) and high content screening (HCS);

555 glycolysis-related active compounds for high-throughput and high-content screening.

A unique collection of 729 compounds targeting NF-κB signaling for high throughput screening and high content screening;

A unique collection of 1248 compounds with defined autophagy-inducing or -inhibitory activity for research in autophagy, high throughput screening (HTS) and high content screening (HCS) for new drugs;

Well-chosen 667 compounds with unique structures targeting DNA damage & repair;

A unique collection of 237 Wnt Hedgehog Notch signaling targeted compounds for high throughput and high content screening;

A unique collection of 184 TGF-beta Smad signaling targeted compounds for high throughput and high content screening;

A unique collection of 580 compounds derived from traditional Chinese medicines (TCMs) for promoting blood circulation and removing blood stasis.

A unique collection of 509 CNS-Penetrant compounds for high throughput screening (HTS) and high content screening (HCS);

419 well-chosen unique anti-parasitic small molecules;